Dutch biopharmaceutical company Crucell expects its operating loss for 2010 to be in the €20-25 million range, citing costs associated with microbial contamination at its Shingal facility in Korea as a key factor.
A new study believes vaccine manufacturers from developing countries may be able to produce a HPV vaccine at a lower cost without infringing on the numerous patents drug makers have taken out on the vaccine technology.
Electroporation specialist Inovio Biomedical Corp and vaccine
developer VGX Pharmaceuticals believe that their recently announced
merger will create a firm capable of rapidly moving DNA vaccine
candidates from the laboratory to the...
NanoImaging Services has opened what it claims is a first of its
kind fee-for-service imaging business to enable structural
characterisation and validation of biological drugs throughout the
GlaxoSmithKline's cervical cancer vaccine, Cervarix, has received a
positive opinion from the European Commission for Human Medicinal
Products (CHMP), bringing a competitor to Merck & Co's dominant
Gardasil vaccine a...
LabTechnologist.com brings you its periodic round up of industry
news, with Qiagen agreeing to buy Digene, Roche Diagnostics
settling a tax evasion investigation and agreements between Bio-Rad
and Beckman Coulter, Waters and Rosetta...
The US Congress has asked the country's National Institute of
Environmental Health Sciences (NIEHS) to conduct research on the
connection between vaccines containing mercury and neurological
disorders, further battering public...
GlaxoSmithKline (GSK) publishes its fourth quarter earnings, which
indicate a significant profit rise well ahead of industry
predictions, with momentum building in its product pipeline of new
drugs giving the company the go-ahead...
A technique that boosts the laboratory production of human
papillomavirus by 1,000 times compared to existing methods could
accelerate research into new treatments for HPV infection, which
causes genital warts and cervical cancer,...
GlaxoSmithKline has announced plans to acquire the Corixa
Corporation, which represents an important strategic deal for GSK's
vaccines division, GSK Bio. The division is the only major vaccine
maker with active R&D programs...
The prospect of a simple vaccination to prevent cervical cancer
took a major step with the publication of positive Phase II trial
results on a candidate from Merck, called Gardasil, in the April
edition of the medical journal The...